Individualizing Incentives for Alcohol in the Severely Mentally Ill
Part of paid clinical trials in Seattle, Washington.
- Sponsor
- Washington State University
- Study ID
- NCT03481049
- Status
- Completed
Conditions
- Alcohol Dependence
- Bipolar Disorder
- Major Depressive Disorder
- Schizophrenia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Accepted
Interventions
- Usual CM — BEHAVIORALBehavioral reinforcement for alcohol abstinence
- High-Magnitude CM — BEHAVIORALBehavioral reinforcement for alcohol abstinence
- Shaping CM — BEHAVIORALBehavioral reinforcement for alcohol abstinence
Study Details
The investigators will evaluate the efficacy of a 2 various contingency management (CM) interventions (High-Magnitude CM, Shaping CM) for treating heavy drinking among individuals with serious mental illness and alcohol dependence who are seen within the context of a community mental health center setting. Participants will be 400 adults diagnosed with serious mental illness and alcohol dependence and those who demonstrate heavy drinking during the first 4 weeks will be randomized to receive treatment conditions.
Key Dates
- Start date
- May 5, 2018
- Status verified
- Aug 2025
- Primary completion
- Jun 3, 2024
- Completion
- Nov 22, 2024
Study Design
- Enrollment
- 392 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Usual CMParticipants will earn at least 3 prize draws each time they submit an alcohol negative urine samples during weeks 5-20, plus treatment as usual
- Experimental: High-Magnitude CMParticipants will earn twice as many prize draws than those in the Usual CM for alcohol abstinence during weeks 5-20, plus treatment as usual.
- Experimental: Shaping CMParticipants will earn prize draws for light drinking during weeks 5-8 instead of alcohol abstinence and will then earn prize draws for abstinence during weeks 9-20, plus treatment as usual.
Primary Outcome Measure
Alcohol Use Assessed by Ethyl Glucuronide (EtG) Detection in Urine [ Time Frame: During weeks 5 -16 of treatment ]
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Sound Health | Seattle | Washington | 98014 | - |
| WSU Research Clinic | Spokane | Washington | 99202 | - |
Find similar trials in Seattle, WA
By condition
By specialty
By research site
Related Studies
- Combination of Novel Therapies for CKD Comorbid DepressionPHASE2 · Recruiting · Stony Brook University · Stony Brook, New York
- Long-term Safety Extension Study of OLZ/SAM in Pediatric SubjectsPHASE3 · Enrolling By Invitation · Alkermes, Inc. · Dothan, Alabama
- Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderPHASE3 · Recruiting · Alkermes, Inc. · Dothan, Alabama
- An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaPHASE3 · Recruiting · Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Phoenix, Arizona